CLINICAL TRIALS PROFILE FOR NOLVADEX

All Clinical Trials for NOLVADEX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003099 ↗	Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1996-05-01	RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of fenretinide and tamoxifen before surgery may be an effective way to prevent the recurrence of or further development of breast cancer. PURPOSE: Randomized phase II trial to study the effectiveness of fenretinide and tamoxifen given before surgery in treating women with breast cancer.
NCT00003099 ↗	Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer	Completed	M.D. Anderson Cancer Center	Phase 2	1996-05-01	RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of fenretinide and tamoxifen before surgery may be an effective way to prevent the recurrence of or further development of breast cancer. PURPOSE: Randomized phase II trial to study the effectiveness of fenretinide and tamoxifen given before surgery in treating women with breast cancer.
NCT00003199 ↗	Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1997-11-01	This phase II trial studies how well giving combination chemotherapy and peripheral blood stem cell transplant followed by aldesleukin and sargramostim works in treating patients with inflammatory stage IIIB or metastatic stage IV breast cancer. Drugs used in chemotherapy, such as busulfan, melphalan, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. This may allow more chemotherapy to be given so that more tumor cells are killed. Aldesleukin may stimulate the white blood cells to kill breast cancer cells. Giving aldesleukin together with sargramostim may kill more tumor cells
NCT00003199 ↗	Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer	Completed	Fred Hutchinson Cancer Research Center	Phase 2	1997-11-01	This phase II trial studies how well giving combination chemotherapy and peripheral blood stem cell transplant followed by aldesleukin and sargramostim works in treating patients with inflammatory stage IIIB or metastatic stage IV breast cancer. Drugs used in chemotherapy, such as busulfan, melphalan, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. This may allow more chemotherapy to be given so that more tumor cells are killed. Aldesleukin may stimulate the white blood cells to kill breast cancer cells. Giving aldesleukin together with sargramostim may kill more tumor cells
NCT00005908 ↗	Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2000-06-01	This study will assess the usefulness of a technique called complementary deoxyribonucleic acid (cDNA) microarray-an examination of a wide array of genes to identify disease-associated patterns-for measuring tumor response to chemotherapy in breast cancer patients. The study will look for "markers" that can help select the most effective type of chemotherapy. It will also evaluate the safety and effectiveness of a new drug combination of capecitabine and docetaxel. Patients age 18 years and older with stage II or III breast cancer whose tumor is 2 centimeters or larger may be eligible for this study. Those enrolled will be treated with surgery, standard chemotherapy using doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan), and the capecitabine and docetaxel combination. Patients will have a physical examination, mammogram and magnetic resonance imaging to evaluate their tumor before beginning treatment. They will then have four 21-day treatment cycles of docetaxel and capecitabine, as follows: docetaxel intravenously (through a vein) on day 1 and capecitabine pills (by mouth) twice a day from days 2 through 15. No drugs will be given from days 16 through 21. This regimen will be repeated four times, after which the tumor will be re-evaluated by physical examination, mammogram, and magnetic resonance imaging. Patients will then have surgery to remove the cancer-either lumpectomy with removal of the underarm lymph nodes; mastectomy and removal of the underarm lymph nodes; or modified radical mastectomy. After recovery, they will have four more cycles of chemotherapy, this time with a doxorubicin and cyclophosphamide. Both drugs will be given intravenously on day 1 of four 21-day cycles. Some patients who had a mastectomy (depending on their tumor characteristics and whether tumor cells were found in their lymph nodes) and all those who had a lumpectomy will also have radiation therapy. Patients with hormone receptor-positive tumors will also receive tamoxifen treatment for 5 years. In addition to the above procedures, all patients will have tumor biopsies (removal of a small piece of tumor tissue) before beginning treatment, on day 1 of cycle 1, before cycle 2, and at the time of surgery, and physical examinations, chest X-rays, bone scans, computerized tomography (CT) scans, electrocardiograms, multi-gated acquisition scan-MUGA (nuclear medicine test of cardiac function) or echocardiograms of heart function, mammograms and blood tests at various times during the study. Patients will be followed at National Institutes of Health (NIH) for 3 years after diagnosis with physical examinations, blood tests, X-rays, and computed tomography (CT) scans. Although it is not known whether this treatment will help an individual patient's cancer, possible benefits are tumor shrinkage and decreased risk of disease recurrence. In addition, the information gained about genetic changes after chemotherapy will help determine if additional studies on the use of cDNA microarray to measure tumor response are warranted.
NCT00005970 ↗	Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer	Completed	Canadian Cancer Trials Group	Phase 3	2000-05-19	This randomized phase III trial studies doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and trastuzumab to see how well they work compared to combination chemotherapy alone in treating women with breast cancer that is human epidermal growth factor receptor 2 (HER2)-positive and has spread to the lymph nodes or high-risk and has not spread to the lymph nodes. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without trastuzumab in treating breast cancer.

Clinical Trial Conditions for NOLVADEX

Condition Name

Condition Name for NOLVADEX
Intervention	Trials
Breast Cancer	33
Stage IIIB Breast Cancer	9
Stage IIIA Breast Cancer	8
Stage IV Breast Cancer	6

Condition MeSH

Condition MeSH for NOLVADEX
Intervention	Trials
Breast Neoplasms	57
Carcinoma	9
Carcinoma in Situ	6
Hemorrhage	4

Clinical Trial Locations for NOLVADEX

Trials by Country

Trials by Country for NOLVADEX
Location	Trials
United States	575
Canada	49
Italy	21
China	20
Ireland	16

Trials by US State

Trials by US State for NOLVADEX
Location	Trials
California	21
Illinois	17
Pennsylvania	17
Texas	17
Massachusetts	16

Clinical Trial Progress for NOLVADEX

Clinical Trial Phase

Clinical Trial Phase for NOLVADEX
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	30
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for NOLVADEX
Clinical Trial Phase	Trials
Completed	47
Active, not recruiting	11
Recruiting	7

Clinical Trial Sponsors for NOLVADEX

Sponsor Name

Sponsor Name for NOLVADEX
Sponsor	Trials
National Cancer Institute (NCI)	31
AstraZeneca	19
Pfizer	5

Sponsor Type

Sponsor Type for NOLVADEX
Sponsor	Trials
Other	92
NIH	33
Industry	32

Nolvadex (tamoxifen) clinical trials update, market analysis, and future revenue projection

Last updated: May 26, 2026

What is Nolvadex (tamoxifen) and what clinical-trial updates matter?

Nolvadex is the brand name for tamoxifen citrate, a selective estrogen receptor modulator (SERM) used primarily for ER-positive breast cancer and, in specific settings, breast cancer risk reduction. The product is long off patent in most jurisdictions, and the current market is dominated by generic tamoxifen. Clinical activity today is shaped less by new phase-3 “approval-enabling” trials for Nolvadex and more by:

• Line extensions and population subgroups (adjuvant duration, escalation/de-escalation with other agents).
• Combination regimens in ER-positive disease (including sequencing with endocrine partners).
• Real-world evidence and comparative effectiveness work versus aromatase inhibitors (AIs).
• Safety signal refinement (endometrial cancer, thromboembolic events) and risk mitigation strategies.

What phase-3/registration-grade developments are driving end-market demand?

For tamoxifen, most major practice-changing evidence base comes from earlier landmark trials, with modern studies focused on:

• Duration optimization (e.g., extending adjuvant endocrine therapy beyond initial years).
• Sequencing with ovarian suppression and AIs in pre/peri-menopausal patients.
• Switching strategies after initial therapy on AI or tamoxifen.
• Biomarker-defined subgroups (ER, PR, menopausal status, genomic signatures) to tune benefit-risk.

Which trial endpoints and safety readouts are most cited in current updates?

Market-facing clinical narratives for tamoxifen typically pivot on:

• Disease-free survival (DFS) and overall survival (OS) in adjuvant settings.
• Recurrence-free survival in metastatic or locally advanced settings.
• Venous thromboembolism (VTE) incidence.
• Endometrial pathology rates, including endometrial cancer and hyperplasia.
• Gynecologic monitoring protocols that influence compliance and discontinuation.

What patents protect Nolvadex and how does exclusivity work today?

Nolvadex is not a “current exclusivity” platform. Tamoxifen is an established molecule with expired composition-of-matter protection in major markets. The commercial reality is that:

• Oral generic tamoxifen is broadly available in multiple dosage strengths.
• “Nolvadex” branding is protected mainly through trademark/brand lifecycle, not molecule exclusivity.
• Any remaining enforceable IP is typically limited to formulation, packaging, manufacturing process, or method-of-use in specific jurisdictions and time windows, rather than controlling overall market entry for tamoxifen.

Orange Book status

A full Orange Book mapping requires active listing data for the specific Nolvadex NDA and manufacturer-sponsor records. A market projection that depends on Orange Book exclusivity must be aligned to the exact listed NDA holder and listed patents. Without that mapping, the only business conclusion that holds across most markets is that tamoxifen has generic-driven pricing pressure.

When does Nolvadex lose exclusivity and what does that mean for generic entry risk?

Tamoxifen’s core exclusivity has long passed. Generic entry risk is therefore not tied to “Nolvadex losing exclusivity.” Instead, risk centers on:

• Supply stability and any manufacturing constraints.
• Regulatory compliance in generic plants.
• Price erosion cycles that follow settlement milestones and new approvals.

For business planning, the key question is less “when does Nolvadex lose exclusivity” and more “how much market share can branded Nolvadex sustain versus generics given ongoing price competition.”

Which companies sell tamoxifen and how does competition affect pricing?

The tamoxifen market is a classic generic-heavy oral endocrine segment:

• Incumbent brand presence depends on physician habit, payer contracts, and channel relationships.
• Generics drive bid-based pricing at national and contract levels.
• Pricing is influenced by availability of multiple ANDA suppliers, regional tendering, and substitution rules.

In this segment, the “competitive landscape” typically matters more at the payer and wholesaler level than at the clinical level.

How big is the Nolvadex/tamoxifen market and what drives volume?

Market size for tamoxifen is driven by:

• ER-positive breast cancer incidence (adjuvant endocrine therapy penetration).
• Standard-of-care mix between tamoxifen and AIs by menopausal status.
• Switching patterns between tamoxifen and AI-based regimens.
• Persistence and adherence in long-duration adjuvant therapy.
• Safety-driven discontinuation (VTE, endometrial events), which affects realized treatment duration.

What typically drives growth versus decline?

Tamoxifen demand can grow when:

• ER-positive incidence trends upward.
• Guidelines support endocrine therapy adoption.
• Improved management reduces discontinuation.

Demand can decline when:

• AI use expands at the expense of tamoxifen in certain cohorts.
• More patients use other endocrine strategies with better tolerability.
• Payers restrict branded or higher-cost options.

What is the clinical-trial and evidence outlook for tamoxifen over the next 5 years?

The next 5 years for tamoxifen are likely to be shaped by:

• Incremental improvements in sequencing rather than new approvals for Nolvadex as a standalone branded product.
• Increased emphasis on personalized risk stratification to select the most appropriate endocrine partner.
• Continued safety monitoring studies and risk reduction protocols.

This implies:

• Clinical “update” activity will continue, but it will not reset molecule exclusivity.
• Competitive intensity will remain high, because the core product is commoditized.

How strong is the patent estate for tamoxifen and what enforcement dynamics exist?

For a mature generic molecule, enforcement dynamics typically include:

• Litigation around generic labeling, method-of-use arguments, and carve-outs tied to specific patented claims.
• Sporadic disputes over manufacturing changes or label updates.

Because tamoxifen is widely generic, enforcement is unlikely to produce broad market protection unless a specific patent targets a specific formulation or dosing schedule that is still relevant in the US label. A proper strength assessment requires a current, NDA-specific patent list and legal status, which is not provided here.

What is the likely branded Nolvadex revenue trajectory given generic dominance?

Branded revenue for long-off-patent endocrine drugs commonly shows:

• Persistent baseline volume where branding is contract-favored or where substitution is constrained.
• Gradual share loss or flat volume amid continued payer switching to lower-cost generics.
• Occasional stabilization from contract renewals, but with recurring downward pressure.

A business projection for “Nolvadex” specifically depends on branded share assumptions, pricing elasticity, and payer contract penetration. Without current share and contract pricing inputs, a precise numerical forecast cannot be produced correctly.

Market projection framework for Nolvadex: what drives topline for a legacy SERM?

Even without exact figures, projections must model:

1. Branded share trend versus generic tamoxifen
2. Unit price evolution (rebates, wholesaler pricing, tender effects)
3. Patient volume (incidence, guideline adherence, persistence)
4. Geographic mix (US versus EU5 versus rest-of-world with different tender structures)
5. Channel dynamics (payer policies, PBM formulary placement)

Scenario logic (directional)

• Base case: modest erosion of branded share with stable overall tamoxifen category volume.
• Downside: faster payer switching and price compression, with branded demand shifting to cheaper generics.
• Upside: contract wins and brand-preferred positioning in certain formularies.

Where do biosimilar risks apply for Nolvadex?

Biosimilar risks do not apply in the same way as for biologics. Tamoxifen is a small molecule; competition is via generic and possibly authorized generic formats rather than biosimilars.

What formulation patents matter for Nolvadex?

For commoditized molecules, formulation IP matters only if it covers:

• A particular dosage strength or regimen
• A specific tablet composition and release profile
• A manufacturing process that is required for a specific approved product

Those effects are typically small at the market level unless a formulation is the payer-preferred product.

What generic entry risks exist for tamoxifen if Nolvadex is still marketed?

Generic entry risk is primarily:

• New ANDA approvals increasing supply
• Authorized generics replacing branded inventory under contracts
• Labeling and manufacturing compliance enabling faster substitution

The risk is continuous, not event-driven by patent expiration.

Key Takeaways

• Nolvadex (tamoxifen) is a mature, generic-dominant SERM where clinical trial updates focus on sequencing, duration, and safety optimization rather than new approval-enabling indications.
• Core exclusivity for tamoxifen has long expired; branded share and payer contracting are the primary determinants of Nolvadex commercial performance.
• Market growth is tied to ER-positive breast cancer incidence, endocrine therapy penetration, and persistence, while pricing is driven by generic competition and tender dynamics.
• A numerical branded revenue projection for Nolvadex requires current branded share, contract pricing, and category volume inputs not provided here; without those inputs, any exact forecast would not be business-valid.

FAQs

1. Does Nolvadex still have clinical trials running in ER-positive breast cancer?
2. How does tamoxifen compare with aromatase inhibitors for postmenopausal ER-positive disease?
3. What are the most important safety endpoints for long-term tamoxifen use?
4. Why do payers substitute branded Nolvadex with generic tamoxifen?
5. What dosing forms of tamoxifen most affect market pricing and substitution?

References

1. (No source list provided because the requested clinical-trials update and market projection require current, citable datasets that are not included.)